United States
Securities and Exchange Commission
Washington, D.C. 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 10, 2008
CytoGenix, Inc.
(Exact name of registrant as specified in its charter)
0-26807
(Commission File Number)
Nevada 76-0484097
---------------------------- ------------------
(State or other jurisdiction (IRS Employer
of incorporation) Identification No.)
3100 Wilcrest Drive, Suite 140, Houston, Texas 77042
(Address of principal executive offices) (Zip Code)
(713) 789-0070 Registrant's telephone number,
including area code
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
- --------------------------------------------------------------------------------
Item 8 Other Matters
CytoGenix, Inc. (the "Company") received a letter dated December 5,
2008 from the United States Securities and Exchange Commission (the
"SEC")notifying the Company that the SEC had completed its investigation as to
the Company and they do not intend to recommend any enforcement action by the
SEC against the Company.
The SEC's investigation related to a SOX Whistleblower Complaint filed
by a former employee with The Department of Labor in January of 2007. The SEC
requested information from the Company addressing the allegations and the
Company responded in compliance with that request.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
December 10, 2008 CytoGenix, Inc.
By: /s/ Randy Moseley
----------------------------------------------
Randy Moseley, Principal Financial Officer
- --------------------------------------------------------------------------------